Screening for Hidden Cardiac Amyloidosis in People With Atrial Fibrillation Using AI-ECG and CT
Tests ECG and CT screening for cardiac amyloidosis in adults with atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Early Detection of Concealed Cardiac Amyloidosis Using AI-ECG and CT-Derived Extracellular Volume in Patients With Atrial Fibrillation
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- Samsung Medical CenterSeoul, South KoreaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Samsung Medical Center
- Trial code
- NCT07567508
- Record updated
- 5 May 2026
- Original description
This study investigates the clinical efficacy of a non-invasive screening protocol using AI-ECG and CT-ECV analysis for cardiac amyloidosis. The study targets on atrial fibrillation(AF) patients with "red-flag" indicators.Read full original descriptionShow less
Early Detection of Concealed Cardiac Amyloidosis Using AI-ECG and CT-Derived Extracellular Volume in Patients With Atrial Fibrillation
This study investigates the clinical efficacy of a non-invasive screening protocol using AI-ECG and CT-ECV analysis for cardiac amyloidosis. The study targets on atrial fibrillation(AF) patients with "red-flag" indicators.
Participants are randomized 1:1 into either an early screening or usual care group.
* Early screening group : AI- ECG and/or CT-ECV analysis + AF treatment * Usual care group : AF treatment Both groups followed for 2 years to compare CA detection rates and clinical outcomes.
Inclusion: Adults aged 19 or older who have provided voluntary written informed consent; Patients with a history of AF (paroxysmal or persistent) and one or more red-flag symptoms/signs; Patients who can undergo at least one of the following: AI-ECG analysis or CT-ECV analysis.
Exclusion: Patients previously diagnosed with cardiac amyloidosis (AL or ATTR); Patients with severe heart failure (NYHA class IV) or terminal illness with a life expectancy of less than 1 year; Patients deemed inappropriate for participation by the investigator.